Duvoglustat
Duvoglustat is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target lysosomal alpha-glucosidase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
No data
Commercial
No data
Clinical
No data
Drug
General
| Drug common name | Duvoglustat |
| INN | duvoglustat |
| Description | Duvoglustat is an optically active form of 2-(hydroxymethyl)piperidine-3,4,5-triol having 2R,3R,4R,5S-configuration. It has a role as an EC 3.2.1.20 (alpha-glucosidase) inhibitor, an anti-HIV agent, an anti-obesity agent, a bacterial metabolite, a hypoglycemic agent, a hepatoprotective agent and a plant metabolite. It is a 2-(hydroxymethyl)piperidine-3,4,5-triol and a piperidine alkaloid. |
| Classification | Small molecule |
| Drug class | enzyme inhibitors: glucosyltransferase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 19130-96-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL307429 |
| ChEBI ID | 44369 |
| PubChem CID | 29435 |
| DrugBank | DB03206 |
| UNII ID | FZ56898FLE (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use